Find a Clinical Trial

Changes in Skeletal Muscle Thickness in Patients with Acute Heart Failure.

18-100

Learn more

3D Stent Evaluation

3D Stent Evaluation

18+

Learn more

A Modified Ketogenic, Anti‐Inflammatory Diet for Patients with High‐Grade Gliomas

A Modified Ketogenic, Anti-Inflammatory Diet for Patients with High-Grade Gliomas

18+

Learn more

AGENT IDE

A Prospective, Randomized (2:1), Multicenter Trial to Assess the Safety and Effectiveness of the AgentTM Paclitaxel Coated PTCA Balloon Catheter for the Treatment of Subjects with In-Stent Restenosis (ISR)

18+

Learn more

The ImmuneSense Study

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma – The ImmuneSense Study

18-70

Learn more

A Safety and Feasibility Study of Percutaneous Delivery of an Arterial VA-ECMO Cannula into the Aorta

A Safety and Feasibility Study of Percutaneous Delivery of an Arterial VA-ECMO Cannula into the Aorta

18-75

Learn more

ASTRID-HF

A SkeleTal muscle Recovery Intervention with Dietary protein in Heart Failure (ASTRID-HF)

18-100

Learn more

Acute Hemodynamics in Patients on AMCS

Acute Hemodynamics in Patients on AMCS

18+

Learn more

A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1

An open-label Phase II randomized trial of BNT113 in combination with
pembrolizumab versus pembrolizumab monotherapy as a first line therapy in
patients with unresectable recurrent, or metastatic Head and Neck
Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma
virus 16 (HPV16+) and expresses PD-L1

18+

Learn more

Non-Interventional Fresh Tumor Tissue

Analysis Of Cell Count, Viability, And Of Fresh Newly Diagnosed Glioblastoma Tissue

18+

Learn more